Loading stock data…
COR
$304.00-4.01 (-1.30%)
Market ClosedLast close May 1
Cencora, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cencora, Inc. in the Healthcare sector is trading at $304.00. The stock is currently 19% below its 52-week high of $377.54, remaining 7.2% below its 200-day moving average. Technical signals show neutral RSI of 35 and bearish MACD signal, explaining why COR maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 35) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$304.00
Potential Upside
2.2%
Whystock Fair Value$310.80
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus12 analysts
Buy
Mean target$402.92+32.5%
Range$340.00 – $447.00
Fundamentals
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home hea...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$59.97B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
37.06
Beta
Defensive asset. Lower volatility than the S&P 500.
0.72
Div Yield
Strong income play. Yield provides a meaningful total return floor.
78.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
99.42%
Volume
Today's trading volume
1.35M
Recent News
Seeking Clues to Cencora (COR) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
Beyond analysts' top-and-bottom-line estimates for Cencora (COR), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2026.
Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardinal Health lifts annual profit forecast on strong demand for specialty drugs
April 30 Reuters) - Drug distributor Cardinal Health on Thursday raised its 2026 profit forecast range, betting on strong demand for costly specialty medicines and branded drugs at its pharmaceuticals
2 Things Matter Most in Picking Winning Stocks, Says This Market Pro
Adam Parker’s Trivariate Research analyzes stocks from a macro, fundamental, and quantitative perspective.
Cencora (COR) Reports Next Week: Wall Street Expects Earnings Growth
Cencora (COR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.